NEW BIOMARKERS FOR DIAGNOSIS AND MONITORING OF MULTIPLE SCLEROSIS

This invention provides an in-vitro method (biomarkers) to diagnose and/or monitor multiple sclerosis patients.

TYPE OF DEVELOPMENT
Diagnostic and/or prognostic tool.

DESCRIPTION
Multiple sclerosis (MS) is a demyelinating and autoimmune disease that affects over 2.5 million people all over the world. MS is the second cause of disability in adults aged 20-40. It entails a high cost for the health system, mainly because of the treatments, disease chronicity and the disability it causes.

The disease is diagnosed following a set of criteria (McDonald criteria); however, other tools are required to improve these criteria in order to achieve early diagnosis, so this is a priority in MS research.

In this sense, a marker that allows monitoring of patients’ response to drugs is required.

There are currently no short-term biomarkers and most of the time the sample required must be of cerebrospinal fluid.

This invention offers a new method to diagnose MS and monitor patients’ response to drugs.

ADVANTAGES
• Non-invasive method (blood sample).
• Simple, fast and reliable.

USE
• Diagnosis of multiple sclerosis.
• Monitoring of MS patients’ response to drugs.

PROTECTION
Spanish Patent Application (P202030782)
Priority Date: 28/07/2020
Applicants: Administration of the Autonomous Community of the Basque Country.

COOPERATION GOAL
• Company interested in the license and commercialisation of the product.

CONTACT
Amaia Albandoz
Research Results Transfer Office (OTRI)
amaia@bioef.eus Tel.: +34 944 53 68 49